Laws: Cases and Codes : U.S. Code : Title 35 : Section 103


   
U.S. Code as of: 01/19/04
Section 103. Conditions for patentability; non-obvious subject matter

      (a) A patent may not be obtained though the invention is not
    identically disclosed or described as set forth in section 102 of
    this title, if the differences between the subject matter sought to
    be patented and the prior art are such that the subject matter as a
    whole would have been obvious at the time the invention was made to
    a person having ordinary skill in the art to which said subject
    matter pertains. Patentability shall not be negatived by the manner
    in which the invention was made.
      (b)(1) Notwithstanding subsection (a), and upon timely election
    by the applicant for patent to proceed under this subsection, a
    biotechnological process using or resulting in a composition of
    matter that is novel under section 102 and nonobvious under
    subsection (a) of this section shall be considered nonobvious if - 
        (A) claims to the process and the composition of matter are
      contained in either the same application for patent or in
      separate applications having the same effective filing date; and
        (B) the composition of matter, and the process at the time it
      was invented, were owned by the same person or subject to an
      obligation of assignment to the same person.

      (2) A patent issued on a process under paragraph (1) - 
        (A) shall also contain the claims to the composition of matter
      used in or made by that process, or
        (B) shall, if such composition of matter is claimed in another
      patent, be set to expire on the same date as such other patent,
      notwithstanding section 154.

      (3) For purposes of paragraph (1), the term "biotechnological
    process" means - 
        (A) a process of genetically altering or otherwise inducing a
      single- or multi-celled organism to - 
          (i) express an exogenous nucleotide sequence,
          (ii) inhibit, eliminate, augment, or alter expression of an
        endogenous nucleotide sequence, or
          (iii) express a specific physiological characteristic not
        naturally associated with said organism;

        (B) cell fusion procedures yielding a cell line that expresses
      a specific protein, such as a monoclonal antibody; and
        (C) a method of using a product produced by a process defined
      by subparagraph (A) or (B), or a combination of subparagraphs (A)
      and (B).

      (c) Subject matter developed by another person, which qualifies
    as prior art only under one or more of subsections (e), (f), and
    (g) of section 102 of this title, shall not preclude patentability
    under this section where the subject matter and the claimed
    invention were, at the time the invention was made, owned by the
    same person or subject to an obligation of assignment to the same
    person.



Previous [Notes] Next

Related Resources

Patent Law Guide

Patent and Trademark Summary

Sample Patent Contracts

Intellectual Property Discussion

Ads by FindLaw